T1	PROC 84 101	búsqueda de dosis
#1	AnnotatorNotes T1	C4764141; Dose Finding Study; Research Activity
T2	PROC 107 138	evaluar la eficacia y seguridad
#2	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
T3	DISO 181 224	hipercolesterolemia familiar heterocigótica
#3	AnnotatorNotes T3	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T4	PROC 294 311	búsqueda de dosis
#4	AnnotatorNotes T4	C4764141; Dose Finding Study; Research Activity
T5	PROC 340 371	evaluar la eficacia y seguridad
#5	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity
T6	DISO 414 457	hipercolesterolemia familiar heterocigótica
#6	AnnotatorNotes T6	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T7	DISO 514 533	Hipercolesterolemia
#7	AnnotatorNotes T7	C0020443; Hypercholesterolemia; Disease or Syndrome
T8	PROC 723 734	diagnóstico
#8	AnnotatorNotes T8	C0011900; Diagnosis; Diagnostic Procedure
T9	DISO 738 781	hipercolesterolemia familiar heterocigótica
#9	AnnotatorNotes T9	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
T10	CHEM 875 884	estatinas
#10	AnnotatorNotes T10	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T11	CHEM 917 926	estatinas
#11	AnnotatorNotes T11	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T12	CHEM 957 966	estatinas
#12	AnnotatorNotes T12	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T13	CHEM 142 152	alirocumab
#13	AnnotatorNotes T13	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	PROC 1437 1461	consentimiento informado
#14	AnnotatorNotes T14	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T15	DISO 1646 1671	hiperlipidemia secundaria
#15	AnnotatorNotes T15	C0853689; Secondary hyperlipidemia; Disease or Syndrome
T16	PROC 1675 1686	Diagnóstico
#16	AnnotatorNotes T16	C0011900; Diagnosis; Diagnostic Procedure
T17	DISO 938 950	intolerancia
#17	AnnotatorNotes T17	C0277585; Intolerance to drug; Pathologic Function
T18	DISO 1690 1731	hipercolesterolemia familiar homocigótica
T19	PROC 1760 1794	tratamiento de aféresis de lípidos
T20	PROC 842 850	tratados
#18	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	CHEM 375 385	alirocumab
#19	AnnotatorNotes T21	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	DISO 1922 1955	diabetes mellitus tipo 1 o tipo 2
T23	DISO 1985 2004	enfermedad tiroidea
#20	AnnotatorNotes T23	C0040128; Thyroid Diseases; Disease or Syndrome
T24	DISO 2034 2046	hipertensión
#21	AnnotatorNotes T24	C0020538; Hypertensive disease; Disease or Syndrome
T25	CHEM 2050 2063	Triglicéridos
#22	AnnotatorNotes T25	C0041004; Triglycerides; Biologically Active Substance · Organic Chemical
T26	PROC 2050 2073	Triglicéridos en ayunas
#23	AnnotatorNotes T26	C3835804; serum or plasma triglycerides fasting; Therapeutic or Preventive Procedure
T27	DISO 2140 2159	Insuficiencia renal
#24	AnnotatorNotes T27	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T28	PROC 793 803	genotipado
#25	AnnotatorNotes T28	C1285573; Genotype determination; Laboratory Procedure
T29	CHEM 1081 1084	LDL
#26	AnnotatorNotes T29	C0023823; Low-Density Lipoproteins; Biologically Active Substance · Organic Chemical
T30	PROC 2293 2302	analítica
#27	AnnotatorNotes T30	C0002778; Analysis of substances; Laboratory Procedure | C0814047; biological analysis and measurement; Laboratory Procedure
T31	PROC 674 698	consentimiento informado
#28	AnnotatorNotes T31	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T32	PROC 1079 1084	C LDL
T33	ANAT 1200 1208	corporal
#29	AnnotatorNotes T33	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T34	CHEM 1787 1794	lípidos
#30	AnnotatorNotes T34	C0023779; Lipids; Organic Chemical
T35	PROC 246 261	Estudio abierto
#31	AnnotatorNotes T35	C1709323; Open Label Study; Research Activity
T36	ANAT 1996 2004	tiroidea
#32	AnnotatorNotes T36	C0040132; Thyroid Gland; Body Part, Organ, or Organ Component | C1278878; Entire thyroid gland; Body Part, Organ, or Organ Component
T38	ANAT 2154 2159	renal
#33	AnnotatorNotes T38	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T39	PROC 2243 2246	ALT
#34	AnnotatorNotes T39	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T40	PROC 2249 2252	AST
#35	AnnotatorNotes T40	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T41	DISO 783 787	HFhe
T42	PROC 903 906	TML
#36	AnnotatorNotes T42	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T43	PROC 909 912	TML
#37	AnnotatorNotes T43	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T44	Date 12 16	2015
T45	Duration 55 67	ocho semanas
T46	LIVB 156 161	niños
#38	AnnotatorNotes T46	C0008059; Child; Age Group
T47	Duration 265 277	ocho semanas
T49	LIVB 389 394	niños
#39	AnnotatorNotes T49	C0008059; Child; Age Group
T50	LIVB 566 601	Niños y adolescentes de ambos sexos
#40	AnnotatorNotes T50	C0870221; Boys; Age Group + C0870604; Female child; Age Group + C0001588; Adolescent, Female; Age Group + C0001588; Adolescent, Male; Age Group
T51	Age 626 643	entre 8 y 17 años
T52	LIVB 706 715	Pacientes
#41	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	LIVB 832 841	Pacientes
#42	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Dose 855 864	una dosis
T55	Neg_cue 891 894	sin
T56	Neg_cue 913 916	sin
T57	Dose 969 986	una dosis estable
T58	Duration 995 1013	al menos 4 semanas
T59	LIVB 1065 1074	Pacientes
#43	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T61	LIVB 1181 1190	Pacientes
#44	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	LIVB 1241 1250	Pacientes
#45	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	Age 1275 1291	entre 8 y 9 años
T64	LIVB 1318 1327	pacientes
#46	AnnotatorNotes T64	C0030705; Patients; Patient or Disabled Group
T66	LIVB 1521 1529	paciente
#47	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	PHYS 1562 1573	comprensión
#48	AnnotatorNotes T67	C0162340; Comprehension; Mental Process
T68	LIVB 1633 1641	Paciente
#49	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	LIVB 1735 1743	Paciente
#50	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	Duration 1798 1809	los 2 meses
T74	LIVB 164 176	adolescentes
#51	AnnotatorNotes T74	C0205653; Adolescent (age group); Age Group
T77	LIVB 397 409	adolescentes
#52	AnnotatorNotes T77	C0205653; Adolescent (age group); Age Group
T48	Age 1352 1370	entre 10 y 17 años
T65	PROC 1397 1403	Tanner
#53	AnnotatorNotes T65	C0431029; Tanner bone age assessment; Diagnostic Procedure
T75	PROC 1309 1315	Tanner
#54	AnnotatorNotes T75	C0431029; Tanner bone age assessment; Diagnostic Procedure
T60	Date 1047 1056	Semana -2
T76	Date 1163 1172	Semana -2
T71	Date 2126 2135	Semana -2
T72	Date 2228 2237	Semana -2
T37	PROC 1195 1208	peso corporal
#55	AnnotatorNotes T37	C2985231; Body Weight Measurement; Diagnostic Procedure
T73	PROC 2207 2226	visita de selección
#56	AnnotatorNotes T73	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T78	PROC 2105 2124	visita de selección
#57	AnnotatorNotes T78	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T79	PROC 1026 1045	visita de selección
#58	AnnotatorNotes T79	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T80	PROC 1142 1161	visita de selección
#59	AnnotatorNotes T80	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A1	Population_data T46 Age
A2	Population_data T74 Age
A3	Assertion T42 Negated
A4	Assertion T11 Negated
A5	Population_data T50 Age
A7	Population_data T49 Age
A8	Population_data T77 Age
A6	Status T22 History_of
A9	Status T23 History_of
A10	Status T24 History_of
A11	Status T19 History_of
#60	AnnotatorNotes T41	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
#61	AnnotatorNotes T18	C0342882; Familial hypercholesterolemia - heterozygous; Disease or Syndrome
#62	AnnotatorNotes T22	C0011854; Diabetes Mellitus, Insulin-Dependent; Disease or Syndrome + C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
#63	AnnotatorNotes T32	C0202117; Low density lipoprotein cholesterol measurement; Laboratory Procedure
T81	Neg_cue 1497 1500	sin
T82	Observation 1504 1516	asentimiento
A12	Assertion T82 Negated
#64	AnnotatorNotes T82	C1302239; Patient consented to clinical trial; Finding (?)
R1	Negation Arg1:T55 Arg2:T42
T83	Quantifier_or_Qualifier 895 902	otro(s)
A13	Assertion T83 Negated
R2	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T83
R3	Negation Arg1:T55 Arg2:T83
R4	Negation Arg1:T56 Arg2:T11
R5	Negation Arg1:T81 Arg2:T82
T84	PROC 44 51	Estudio
#65	AnnotatorNotes T84	C0008976; Clinical Trials; Research Activity
R6	Has_Duration_or_Interval Arg1:T84 Arg2:T45
R7	Experiences Arg1:T46 Arg2:T13
R8	Experiences Arg1:T46 Arg2:T3
R9	Experiences Arg1:T74 Arg2:T13
R10	Experiences Arg1:T74 Arg2:T3
R11	Has_Duration_or_Interval Arg1:T35 Arg2:T47
R12	Experiences Arg1:T49 Arg2:T21
R13	Experiences Arg1:T49 Arg2:T6
R14	Experiences Arg1:T77 Arg2:T21
R15	Experiences Arg1:T77 Arg2:T6
R16	Has_Age Arg1:T50 Arg2:T51
R17	Overlap Arg1:T31 Arg2:T51
R18	Experiences Arg1:T52 Arg2:T9
R19	Experiences Arg1:T52 Arg2:T41
R20	Experiences Arg1:T52 Arg2:T28
R21	Before Arg1:T28 Arg2:T8
R22	Experiences Arg1:T53 Arg2:T20
R23	Used_for Arg1:T10 Arg2:T20
R24	Has_Dose_or_Strength Arg1:T10 Arg2:T54
R25	Experiences Arg1:T53 Arg2:T42
R26	Experiences Arg1:T53 Arg2:T43
R27	Used_for Arg1:T11 Arg2:T43
R28	Causes Arg1:T12 Arg2:T17
R29	Experiences Arg1:T53 Arg2:T17
R31	Has_Dose_or_Strength Arg1:T12 Arg2:T57
R32	Has_Duration_or_Interval Arg1:T12 Arg2:T58
R33	Before Arg1:T12 Arg2:T79
R34	Overlap Arg1:T79 Arg2:T60
R35	Before Arg1:T12 Arg2:T60
R36	Combined_with Arg1:T10 Arg2:T42
R37	Combined_with Arg1:T10 Arg2:T43
R38	Experiences Arg1:T59 Arg2:T32
T85	Result_or_Value 1095 1135	mayor o igual a 130 mg/dl (≥3,37 mmol/l)
R39	Has_Result_or_Value Arg1:T32 Arg2:T85
R40	Overlap Arg1:T32 Arg2:T80
R41	Overlap Arg1:T32 Arg2:T76
T86	Result_or_Value 1209 1233	superior o igual a 25 kg
R42	Has_Result_or_Value Arg1:T37 Arg2:T86
R43	Location_of Arg1:T33 Arg2:T37
R44	Experiences Arg1:T61 Arg2:T37
R45	Has_Age Arg1:T62 Arg2:T63
T87	Quantifier_or_Qualifier 1296 1305	estadio 1
R46	Has_Quantifier_or_Qualifier Arg1:T75 Arg2:T87
R47	Experiences Arg1:T62 Arg2:T75
R48	Has_Age Arg1:T64 Arg2:T48
R49	Overlap Arg1:T75 Arg2:T63
R50	Overlap Arg1:T65 Arg2:T48
T88	Quantifier_or_Qualifier 1384 1393	estadio 2
R51	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T88
R52	Experiences Arg1:T64 Arg2:T65
R53	Overlap Arg1:T14 Arg2:T67
R54	Overlap Arg1:T82 Arg2:T67
R55	Experiences Arg1:T66 Arg2:T67
R56	Experiences Arg1:T68 Arg2:T15
R57	Experiences Arg1:T69 Arg2:T19
R58	Overlap Arg1:T19 Arg2:T70
T89	PROC 1832 1841	selección
#66	AnnotatorNotes T89	C0242802; Patient Selection; Research Activity
R59	Before Arg1:T19 Arg2:T89
T90	Quantifier_or_Qualifier 1855 1863	previsto
#67	AnnotatorNotes T90	C1301732; Planned; Functional Concept
R60	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T90
R61	Location_of Arg1:T36 Arg2:T23
T91	Result_or_Value 2074 2098	>350 mg/dl (3,95 mmol/l)
R62	Has_Result_or_Value Arg1:T26 Arg2:T91
R63	Overlap Arg1:T26 Arg2:T78
R64	Overlap Arg1:T26 Arg2:T71
T92	Observation 2064 2073	en ayunas
#68	AnnotatorNotes T92	C0015663; Fasting; Finding
R65	Overlap Arg1:T26 Arg2:T92
R66	Location_of Arg1:T38 Arg2:T27
T93	Result_or_Value 2182 2200	<30 ml/min/1,73 m2
T94	PROC 2177 2181	TFGe
#69	AnnotatorNotes T94	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
R67	Has_Result_or_Value Arg1:T94 Arg2:T93
R69	Overlap Arg1:T94 Arg2:T73
R70	Overlap Arg1:T94 Arg2:T72
R71	Overlap Arg1:T27 Arg2:T73
T95	Quantifier_or_Qualifier 2160 2165	grave
#70	AnnotatorNotes T95	C1547227; Severe - Severity of Illness Code; Intellectual Product
R72	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T95
T96	Result_or_Value 2253 2261	>2 x LSN
R73	Has_Result_or_Value Arg1:T39 Arg2:T96
R74	Has_Result_or_Value Arg1:T40 Arg2:T96
T97	Quantifier_or_Qualifier 2274 2286	1 repetición
R75	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T97
T98	CONC 2263 2273	se permite
#71	AnnotatorNotes T83	C0205394; Other; Qualitative Concept
R30	Experiences Arg1:T53 Arg2:T79
T99	PROC 1885 1892	estudio
#72	AnnotatorNotes T99	C0008976; Clinical Trials; Research Activity
R76	Overlap Arg1:T19 Arg2:T99
#73	AnnotatorNotes T19	C2599009; LDL apheresis procedure; Therapeutic or Preventive Procedure | C0949035; Low density lipoprotein apheresis; Therapeutic or Preventive Procedure
A14	Experiencer T46 Patient
A15	Experiencer T74 Patient
A16	Experiencer T49 Patient
A17	Experiencer T77 Patient
A18	Experiencer T50 Patient
A19	Experiencer T52 Patient
A20	Experiencer T53 Patient
A21	Experiencer T59 Patient
A22	Experiencer T61 Patient
A23	Experiencer T62 Patient
A24	Experiencer T64 Patient
A25	Experiencer T66 Patient
A26	Experiencer T68 Patient
A27	Experiencer T69 Patient
A28	Assertion T17 Hypothetical
A29	Assertion T12 Hypothetical
A30	Status T19 Future
